Forte Biosciences Inc FBRX

Healthcare Biotechnology

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

NDAQ:FBRX - Post by User

Forte Biosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by ApexWealth99on Nov 25, 2024 10:20am

16 Views

Post# 36328949

Bullish Setups in $FBRX and $MYNZ

$FBRX is forming a bullish flag near $16 after its recent breakout, with consolidation suggesting another leg up.

$MYNZ gains attention ahead of the FDA's GenAI conference, highlighting its diagnostic potential. Both are positioned for upside moves.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale